...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Polyclonal T-cell reconstitution of X-SCID recipients after in utero transplantation of lymphoid-primed multipotent progenitors
【24h】

Polyclonal T-cell reconstitution of X-SCID recipients after in utero transplantation of lymphoid-primed multipotent progenitors

机译:X-SCID受体的多克隆T细胞重建在子宫内移植淋巴液引发的多能祖细胞后

获取原文
获取原文并翻译 | 示例

摘要

Although successful in utero hematopoi-etic cell transplantation (IUHCT) of X-linked severe combined immune deficiency (X-SCID) with enriched stem and progenitor cells was achieved more than a decade ago, it remains applied only in rare cases. Although this in part reflects that postnatal transplantations have overall given good results, there are no direct comparisons between IUHCT and postnatal transplantations of X-SCID. The proposed tolerance of the fetal immune sys-tem to foreign human leukocyte antigen early in gestation, a main rationale behind IUHCT, has recently been challenged by evidence for a considerable immune barrier against in utero transplanted alloge-neic bone marrow cells. Consequently, there is need for further exploring the application of purified stem and progenitor cells to overcome this barrier also in IUHCT. Herein, we demonstrate in a con-genic setting that recently identified lymphoid-primed multipotent progenitors aresuperior to hematopoietic stem cells in providing rapid lymphoid reconstitution after IUHCT of X-SCID recipients, and sustain in the long-term B cells, polyclonal T cells, as well as short-lived B-cell progenitors and thymic T-cell precursors. We further provide evidence for IUHCT of hematopoietic stem cells giving superior B- and T-cell reconstitution in fetal X-SCID recipients compared with neonatal and adolescent recipients.
机译:尽管十多年前成功实现了X连锁严重联合免疫缺陷症(X-SCID)与富集的干细胞和祖细胞的子宫造血细胞移植(IUHCT),但它仅在极少数情况下适用。尽管这部分反映出产后移植总体上取得了良好的效果,但是IUHCT与X-SCID的产后移植之间没有直接的比较。 IUHCT背后的一个主要原理是,胎儿免疫系统在妊娠早期对外来人类白细胞抗原的耐受性受到了针对子宫移植同种异体骨髓细胞相当大的免疫屏障的证据的挑战。因此,需要进一步探索纯化的干细胞和祖细胞的应用以克服IUHCT中的这一障碍。在这里,我们在一个同基因环境中证明,最近鉴定出的淋巴液引发的多能祖细胞在造血干细胞方面优于X-SCID受体,在提供IUHCT后可快速进行淋巴液重建,并且长期存在于B细胞,多克隆T细胞,以及寿命短的B细胞祖细胞和胸腺T细胞前体。我们进一步提供的证据表明,与新生儿和青少年相比,胎儿X-SCID接受者造血干细胞的IUHCT具有更好的B细胞和T细胞重构能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号